Psychiatric side effects of non-psychiatric drugs

British Journal of Hospital Medicine

Volumn 71, Issue 8, 2010, Pages 432-436

  Holvey, Carl ^a   Connolly, Anne ^b   Taylor, David ^c  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b Pharmacy Department   (United Kingdom)

^c SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77955948818     PISSN: 17508460     EISSN: None     Source Type: Journal    
DOI: 10.12968/hmed.2010.71.8.77664     Document Type: Conference Paper

References (27)

1. Anonymous (2007) How safe are antipsychotics in dementia? Drug Ther Bull 45: 81-5
2. Barrett PJ, Emmins PD, Clarke PD, Bradley DJ (1996) Comparison of adverse events associated with use of mefloquine and combination of chloroquine and proguanil as antimalarial prophylaxis: postal and telephone survey of travellers. BMJ 313: 525-8
3. Beny A, Paz A, Potasman I (2001 ) Psychiatric problems in returning travellers: Feature and associations. J Travel Med 8: 243-6
4. Bosboom JLW, Wolters EC (2004) Psychotic symptoms in Parkinson's disease: pathophysiology and management. Expert Opin Drug Saf 3(3): 209-20
5. Boudreau E, Schuster B, Sanchez J et al (1993) Tolerability of prophylactic Lariam regimens. Trop Med Parasitol 44(3): 257-65
6. Budur K, Pozuelo L (2003) Olanzapine for corticosteroid-induced mood disorders. Psychosomatic: 44(4): 353
7. Croft M, Whitehouse DP, Cook GC, Beer D (2002) Safety evaluation of the drugs to prevent malaria. Expert Opin Drug Saf 1(1): 19-27
8. Diepernik E, Ho SB, Thuras P et al (2003) A prospective study of ribavirin therapy for patients with chronic hepatitis. Clin Psychosomatics 44(2): 104-12
9. Fernandez HH, Trieschmann ME, Friedman JH (2003) Treatment of psychosis in Parkinson's disease. Drug Saf 26(9): 643-59
10. Goggans FC, Weisberg LJ, Koran LM (1983) Lithium prophylaxis of prednisone psychosis: a case report. J Clin Psych 44: 111-12
11. Hosoda S, Takimura H, Shibayama M et al (2000) Psychiatric symptoms related to interferon therapy for chronic hepatitis C: clinical features and prognosis. Psychiatry Clin Neurosci 54: 565-72
12. Koskinas J, Merkoruraki P, Manesis E et al (2002) Assessment of depression in patients with chronic hepatitis: effect of interferon treatment. Dig Dis 20(3-4): 284-8
13. Kremenchutzky M, Morrow S, Rush C (2007) The safety and efficacy of INF-β products for the treatment of multiple sclerosis. Expert Opin 6(3): 279-88
14. Malek-Ahmadi P, Hilsabek R (2007) Neuropsychiatric complications of interferons: classifications, neurochemical bases, and management. Ann Clin Psych 19(2): 113-23
15. Meco G, Stirpe P, Edito F, Purcaro C, Valente M, Bernardi S and Vanacore N (2009) Aripiprazole in L-dopa-induced dyskinesias: a one-year open-label pilot study. J Neur Transmiss 116(7): 881-4
16. Medicines and Healthcare products Regulatory Authority (2010) Healthcare professional reporting of suspected adverse drug reactions. Medicines and Healthcare products Regulatory Agency www.mhra.gov.uk/SearchHelp/Glossary/index. htm (accessed 9 July 2010)
17. Onyike CU, Bonner JO, Lyketsos CG, Treisman GJ (2004) Mania during treatment of chronic hepatitis C with pegylated interferon and ribavirin. Am J Psychiatry 161: 429-35
18. Overbosch D, Schilthuis H, Bienzle U et al (2001) Atovaquone-proguanil versus mefloquine for malaria prophylaxis in nonimmune travellers: results from a randomized, double-blind study. Clin Infect Dis 33(7): 1015-21
19. Patten SB, Neutel IC (2000) Corticosteroid-induced adverse psychiatric effects. Drug Saf 22(2): 111-22
20. Patten SB, Williams JVA, Love EJ (1996) Self-reported depressive symptoms following treatment with corticosteroids and sedativehypnotics. Int J Psych Med 26: 15-24
21. Pirmohamed M, James S, Meakin S et al (2004) Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ329: 15-19
22. Raison CL, Demetrashivili M, Capuron L, Miller AH (2005) Neuropsychiatric adverse effects of interferon-α. CNS Drugs 19(2): 105-23
23. Robert W, Taylor J, White NJ (2004) Antimalarial drug toxicity. Drug Saf 27(1): 25-61
24. Turktas I, Gucuyener K, Ozden A (1997) Medication-induced psychotic reaction. J Am Acad Child Adolesc Psych 36: 1017-18
25. Vincent FM (1995) The neuropsychiatric complications of corticosteroid therapy. Compr Ther 21: 524-8
26. Weinrieb RM, Auriacombe M, Lynch KG, Chang K, Lewis JD (2003) A critical review of selective serotonin reuptake inhibitor-associated bleeding: balancing the risk of treating hepatitis C-infected patients. J Clin Psych 64(12): 1502-10
27. Zahodne LB, Fernandez HH (2008) Pathophysiology and treatment of psychosis in Parkinson's disease: a review. Drugs Aging 25(8): 665-82